Health CarePharmaceuticals and Biotechnology
  • Price (DKK)346.70
  • Today's Change-1.60 / -0.46%
  • Shares traded560.84k
  • 1 Year change-25.25%
  • Beta0.8486
Data delayed at least 15 minutes, as of Jan 27 2023 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

  • Revenue in DKK (TTM)17.55bn
  • Net income in DKK3.68bn
  • Incorporated2000
  • Employees6.44k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NZYM B:CPH since
Chr Hansen Holding A/SAnnounced12 Dec 202212 Dec 2022Announced-19.56%1.81bn
Chr Hansen Holding A/SAnnounced12 Dec 202212 Dec 2022Announced-19.56%9.62bn
Data delayed at least 15 minutes, as of Jan 27 2023 15:59 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Azelis Group NV26.31bn1.19bn43.73bn3.18k36.652.3824.731.660.6860.68615.1210.560.8425.717.281,113,278.003.91--4.73--23.51--4.65--1.174.370.3537--27.19---4.52------
Oci NV66.49bn10.25bn49.09bn3.72k4.802.362.090.73836.526.5242.3213.270.982912.5811.242,406,394.0027.711.8344.902.5838.2520.6528.194.151.3216.170.388--81.8827.08421.0527.71-19.49--
Arkema SA85.86bn7.81bn51.74bn20.20k6.760.88194.130.602713.7113.71151.44105.120.88295.937.43597,928.008.156.639.848.0723.6821.789.237.981.3832.860.290227.6720.744.79325.3324.819.627.91
Imcd NV30.34bn2.07bn62.20bn4.01k29.965.2022.392.054.904.9071.6328.,090,717.008.305.6411.717.8221.7820.286.844.651.0419.700.450744.4723.8014.9172.5523.2223.7224.12
Umicore SA187.55bn3.93bn63.72bn11.35k15.902.459.650.33982.192.19104.4114.202.577.6311.341,848,767.005.424.899.728.125.856.512.111.840.859910.940.412735.6116.1518.16374.1927.877.673.83
Chr Hansen Holding A/S9.36bn1.70bn65.53bn3.69k38.505.0626.067.0012.9112.9171.2198.300.39363.247.752,535,703.007.148.948.0511.0955.2857.5718.1421.000.960110.440.376962.4613.052.7713.290.0985.96-10.07
Akron PAO16.54bn5.63bn70.59bn11.21k11.527.5110.294.271,562.541,562.544,595.302,395.290.73542.9921.09--25.348.4035.9812.1759.9047.3434.4615.831.10--0.448981.994.385.43-86.33-26.953.50-19.73
Evonik Industries AG135.65bn6.89bn70.71bn33.84k10.250.81164.710.52121.992.0039.2125.140.79364.778.68552,599.704.103.355.084.0124.2028.765.175.130.9184--0.320579.0822.593.2752.970.00-1.540.3454
Novozymes A/S17.55bn3.68bn78.79bn6.44k26.296.9315.244.4913.1913.1962.9650.030.66552.355.322,726,468.0013.9814.7718.7419.5354.5656.2621.0021.310.78124.890.324947.2117.403.8516.853.3411.305.92
Yara International ASA161.14bn14.01bn79.36bn17.80k5.661.493.930.492579.5179.51914.29301.641.394.4010.3613,083,640.0011.722.8116.603.5726.4626.578.453.500.77838.680.3418150.2943.367.93-35.02-9.93-12.0030.70
PhosAgro PAO56.83bn20.06bn80.43bn25.00k4.013.783.501.421,601.041,601.044,535.501,697.701.268.0415.23--44.5816.4762.8821.0152.9843.3835.3018.211.02--0.390491.1565.6317.50665.9916.713.5731.48
Brenntag SE139.36bn6.27bn80.44bn17.20k12.832.198.880.57725.455.45121.2331.991.708.427.181,087,056.007.795.5111.487.6622.4322.244.593.521.1913.350.430741.7221.946.50-3.904.477.506.67
Akzo Nobel NV79.16bn4.02bn88.07bn35.60k22.442.2912.541.113.032.9759.9229.660.73423.734.05324,481.703.944.026.155.6536.6542.735.376.610.787614.000.498676.4212.390.322329.209.04-14.601.30
Data as of Jan 27 2023. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

19.96%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 20218.06m3.55%
Baillie Gifford & Co.as of 19 Jan 20236.93m3.05%
MFS International (UK) Ltd.as of 30 Sep 20226.84m3.01%
The Vanguard Group, Inc.as of 05 Jan 20235.30m2.33%
BlackRock Fund Advisorsas of 05 Jan 20233.64m1.60%
Pictet Asset Management SAas of 31 Dec 20223.38m1.49%
Impax Asset Management Ltd.as of 30 Dec 20223.28m1.45%
Walter Scott & Partners Ltd.as of 19 Jan 20232.73m1.20%
Harding Loevner LPas of 31 Dec 20222.62m1.16%
Amundi Asset Management SA (Investment Management)as of 16 Jan 20232.58m1.13%
More ▼
Data from 31 Dec 2021 - 16 Jan 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.